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Summary
Purpose: To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss. Methods: 451
patients with glioblastoma multiforme (GBM) were randomly assigned after surgery to: Arm A: Carmustine
(BCNU) + standard radiation therapy (SRT); Arm B: BCNU + accelerated radiation therapy (ART: 160 cGy
twice daily for 15 days); Arm C: CDDP + BCNU + SRT; or Arm D: CDDP + BCNU + ART. Patients on arms
C and D received audiograms at baseline, and prior to the start of RT, and prior to cycles 3 and 6. Otologic
toxicities were recorded at each visit. Results: 56% of patients had hearing loss at baseline. 13% and 50% of patients
experienced worsening ototoxicity after 1 year of treatment in arms A and B vs. C and D, respectively, with 13% of
those on arms C and D experiencing significant ototoxicity (‡ grade 3) at 6 months. Increasing age was associated
with an increased risk of ototoxicity. Conclusions: Increased exposure to CDDP increases the risk of ototoxicity over
time. Older patients are more susceptible to hearing loss with CDDP. The low proportion of patients with clinically
significant ototoxicity suggests that baseline screening is unnecessary in GBM patients.
Introduction
Cisplatin (CDDP) is a chemotherapeutic agent used in
the treatment of a variety of malignancies and is a well-
known ototoxic agent. Histopathologic evidence sug-
gests that CDDP first destroys outer hair cells in the
organ of Corti on the basal turn of the cochlea [1,2]. The
outer hair cells are responsible for sensing higher fre-
quencies, and their loss explains the most common
otologic toxicity caused by cisplatin – high frequency
sensorineural hearing loss [3]. With increased cumulative
doses, damage to inner hair cells can occur, resulting in
hearing loss at lower frequencies, including conversa-
tional speech ranges [1,4], additional damages can
include decreased spiral ganglion cells and atrophy of
stria vascularis [4,5].
Cranial radiation can contribute to conductive hear-
ing loss by inducing changes to the middle and external
ear, [6] primarily by increasing the incidence of serous
effusions [5]. The sensorineural aspect of hearing has
generally been thought to be fairly resistant to radiation
damage, although once damage occurs, it is more likely
permanent [6]. One study found that of patients with
parotid tumors treated with irradiation, 50% had clini-
cally relevant hearing loss, and in 33%, this loss was
permanent and affected quality of life [7]. An increased
incidence of hearing loss has been found when CDDP is
given following cranial radiation therapy in children,
suggesting a synergistic toxic effect [8,9]. This does not
appear to hold true when CDDP is given prior to
radiotherapy.
One treatment regimen for glioblastoma multiforme
(GBM) consists of a combination of surgery, BCNU,
and RT. CDDP has been found to have anti-tumor
activity against recurrent glioma with intravenous
administration [10]. It has also been observed to remain
in tissues for extended periods of time following
administration [11]. This may account for its action as a
radiosensitizer of hypoxic cells and its ability to poten-
tiate post-RT cell kill, [12] thus increasing the effective-
ness of the radiation therapy. However, the combination
of CDDP and cranial radiation has the potential to
cause serious ototoxicity [13]. In a recent clinical trial,
this combination was evaluated to determine its effec-
tiveness in prolonging survival of patients with GBM
compared to standard treatment [14]. As a component
of that study, this trial was designed to assess the oto-
toxicity of this treatment regimen.
In this study, we set out to examine the frequency
and severity of otologic complaints, including hearing
loss, tinnitus, and serous otitis media, in patients
diagnosed with GBM and undergoing treatment with
either standard therapy or chemotherapy including
CDDP. Based on the study design, it is also possible to
infer the time period during which hearing loss most
commonly occurred, either during treatment with
CDDP alone, with radiation alone, or with a combi-
nation of the two treatment modalities. We used serial
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pure tone audiograms to determine the incidence and




Patients with newly diagnosed histologically confirmed
glioblastoma multiforme were randomly assigned after
surgical biopsy or excision to one of four treatment arms
as shown in Figure 1. Treatment began within 4 weeks
of surgery. Patients on arms A and B received 200 mg/
m2 intravenous BCNU once every 8 weeks for 6 cycles,
and either SRT consisting of 180 cGy once a day for
36 days or ART with 160 cGy twice daily for 15 days.
Patients on arms C and D received 50 mg/m2 intrave-
nous BCNU days 1–3, every 8 weeks for 2 cycles, then
200 mg/m2 once every 8 weeks for 4 cycles. In addition,
they received 30 mg/m2 intravenous CDDP days 1–3
and 29–31 every 8 weeks for 2 cycles and either SRT or
ART. Patients on arms C and D had 8 weeks of che-
motherapy prior to initiating RT [14].
Patient evaluation
Serial audiograms were requested of all patients receiv-
ing CDDP starting with a baseline audiogram to be
scheduled as soon as the treatment arm was assigned.
Although testing was preferably prior to the initiation of
treatment, commencement of treatment was not to be
delayed. Additional audiograms were to be completed
prior to the start of RT, prior to cycles 3 and 6 BCNU,
and as clinically indicated thereafter.
Assessment of toxicity
At each evaluation, toxicities to be graded included (1)
neuro-hearing and (2) acute radiation toxicity to the ear.
These were evaluated per National Cancer Institute
(NCI) Common Toxicity Criteria grading version 2.0,
which defines ‘neuro-hearing’ toxicity as grade 1:
asymptomatic, hearing loss on audiometry only;
grade 2: tinnitus; grade 3: hearing loss interfering with
function but correctable with hearing aid; grade 4:
deafness not correctable; and ‘acute radiation toxicity to
the ear’ as grade 1: mild external otitis with erythema,
pruritis, secondary to dry desquamation not requiring
medication with audiogram unchanged from baseline;
grade 2: moderate external otitis requiring topical
medication/serous otitis medius/hypoacusis on testing
only; grade 3: severe external otitis with discharge or
moist desquamation/symptomatic hypoacusis/tinnitus,
not drug-related; and grade 4: deafness.
CDDP was to be discontinued if grade 3 neuro-
hearing toxicity was recorded, and the patient was to
continue on BCNU and RT. Quality control of toxicity
monitoring was verified by adhering to NCI guidelines
requiring 10% of all cases accrued to be audited. In
addition, each case was individually reviewed to insure
that all institutions correctly applied the NCI common
toxicity grading scale.
Statistical analysis
Categorical variables were summarized by the observed
frequency and percent. Comparisons of categorical
variables between two groups were performed with a v2
test. Continuous variables were summarized using
mean±SD as well as median and range (minimum to
maximum values). A rank-sum test was used for
comparisons of continuous variables between groups.
All time-to-event outcomes were measured from date
of study enrollment to date of event or last follow-up.
Time-to-event outcomes were estimated via the
Kaplan–Meier method [15]. Comparisons of Kaplan–
Meier estimated time-to-event experiences between two
groups were done with the log-rank test [16]. Uni-
variable Cox proportional hazards models [17] were
used to assess the association between baseline patient
characteristics (age, gender, performance score, extent
of resection, baseline anti-convulsant treatment, base-
line corticosteroid treatment, family history of brain
tumors), baseline pure tone hearing measures (250, 500,
1000, 2000, 3000, 4000, 6000, and 8000 dB), and
treatment arm (C vs. D). No multivariable Cox mod-
eling was performed due to the small number of events.
All tests were two-sided and a P-value £ 0.05 was
considered statistically significant.
Figure 1. Treatment schedule.
Results
A total of 230 patients were enrolled on arms C and D.
Of these, 176 (77%) received a baseline audiogram – 86
(74%) on arm C and 90 (80%) on arm D (see Table 1);
these patients comprised the study group. Patients who
received baseline audiograms were slightly older than
those who did not (56±12 years vs. 53±12 years,
respectively), although this difference did not achieve
statistical significance (P-value = 0.09). In addition,
patients who received baseline audiograms tended to
have a worse performance score than patients who did
not have a baseline audiogram, although this difference
also did not quite achieve statistical significance
(P-value = 0.051). There were no other obvious differ-
ences between patients who received a baseline audio-
gram and those who did not. The study group consisted
of 66 (37%) females and 110 (63%) males. Most of these
patients had a subtotal (57%) or gross total resection
(24%). The majority were being treated with corticos-
teroids and/or anti-convulsants at baseline.
Table 2 summarizes the audiograms that were
obtained. Of the 176 patients, 161 went on to receive
RT, 78 were on arm C and received SRT along with
CDDP and BCNU and the remaining 83 were assigned
to arm D and received ART along with CDDP and
BCNU. Audiograms prior to RT were obtained from 85
(53%) of the 161 patients with baseline audiograms who
received RT: 48 (62%) on arm C and 37 (44%) on arm
D. Although audiograms were stipulated by the proto-
col prior to cycle 3 (immediately post-RT) and prior to
cycle 6, only 19 audiograms were obtained post-radio-
therapy from the 142 patients with baseline audiograms
who started cycle 3: 3 (4%) from arm C and 16 (22%)
from arm D.
On baseline audiograms, 99 (56%) of patients had
some degree of hearing loss, defined as any abnormality
on an audiogram. Of these 99 patients, 84 had loss in
both ears, 7 had loss only in the left ear, and 8 had loss
only in the right ear. The majority of patients with
hearing loss (70%) had losses in frequencies above 3000
dB. After 8 weeks of treatment with CDDP and BCNU
and prior to the initiation of RT treatment, 54 (61%) of
the patients who had an audiogram prior to radiother-
apy had some degree of hearing loss. Of the19 patients
who had an audiogram post-radiotherapy, 12 (63%)
had some degree of hearing loss. There was no evidence
of a difference in hearing loss between arms C and D.
Auditory/hearing adverse events, defined as hearing
loss, otitis, tinnitus, and RT-ear, of grade 1 or higher
were more frequent in patients on arms C or D com-
pared to patients on arms A or B. There was no evidence
of a difference in hearing adverse events between arms C
and D. Forty-one of the 117 (36%) patients on arms C
and 43 of the 113 patients on arm D (38%) reported at
least one hearing related adverse event of grade 1 or
higher. By comparison, 13 of the 111 (12%) of patients
on arm A and 13 of the 110 (12%) on arm B reported at
least one hearing related adverse event of grade 1 or
higher. At 6 months, 15% (95% CI: 9–21) of patients on
arms A or B experienced a hearing related adverse event
of grade 1 or higher compared to 45% (95% CI: 36–52)
of patients on arms C or D (Figure 2). This difference
was statistically significant (P-value<0.001). The most
commonly reported hearing related adverse events on
arms C and D were hearing loss followed by tinnitus.
Defining serious hearing related adverse events as grade
3 or higher, there was no apparent difference in the
occurrence of serious hearing related adverse events
between arms A/B and arms C/D (P-value = 0.19).








N = 176 N = 54
Arm, n(%) 0.28
C 86 (74) 31 (26)
D 90 (80) 23 (20)
Gender, n(%) 1.00
Female 66 (37) 20 (37)
Male 110 (63) 34 (63)
Age, years 0.090
Mean±SD 55.8±11.5 52.8±11.8
Median (min, max) 56.0 (22, 79) 52.8 (29, 78)
Age groups, n(%) 0.075
£ 40 years 16 (9) 10 (19)
40+ to 60 years 96 (55) 31 (57)
>60 years 64 (36) 13 (24)
PS, n(%) 0.051
0 59 (34) 28 (52)
1 93 (53) 20 (37)




Biopsy 33 (19) 13 (24)
STR 100 (57) 22 (41)




Yes 141 (81) 41 (76)





Yes 126 (73) 41 (79)
No 47 (27) 11 (21)
Missing 3 2
Family hx of brain
tumor, n(%)
0.25
Yes 11 (7) 6 (11)
No 158 (93) 48 (89)
Missing 7
Table 2. Summary of audiograms
Characteristics Arm C Arm D
Number enrolled 117 113
No. (%) with baseline audiograms 86 (74) 90 (80)
Number with baseline audiogram
who received RT
78 83
No. (%) with audiogram prior to RT 50 (64) 38 (46)
Number who started cycle 3 with
baseline audiogram
67 73
No. (%) with audiograms post-RT 3 (4) 16 (22)
Specifically, 3% (95% CI: 0–6) of the patients on arms
A or B experienced a serious adverse event by 6 months
compared to 4% (95% CI: 1–7) of patients on arms C or
D (Figure 2).
Conductive hearing loss was much less frequent than
sensorineural hearing loss at baseline. Only 3 (2%) pa-
tients had documented conductive hearing loss at base-
line compared to 51 (29%) patients with sensorineural
loss. These percentages increased after CDDP+ BCNU
therapy to 6 of 88 (7%) with conductive hearing loss and
32 of 88 (36%) with sensorineural hearing loss.
Although the number of patients with a post-RT
audiogram was small, it does not appear as though these
percentages increased post-RT: 0 of 19 (0%) conductive
hearing loss and 6 of 19 (32%) sensorineural.
Figure 3 summarizes the rate of different definitions
of hearing loss for patients on arms C and D. The three
measures are (a) a loss documented by an audiogram in
any pure tone range, (b) a clinically significant hearing
loss – a documented loss on audiogram of greater than
20 dB at any frequency less than 3000 dB, and (c) a
clinically significant hearing loss and/or a hearing
related adverse event of grade 3 or higher. These mea-
sures are not meant to be compared to each other,
Figure 2. Hearing-related adverse events by treatment arm and severity.
Figure 3. Audiogram findings in patients receiving radiation therapy + carmustine + cisplatin.
because they encompass different patient groups and
because the timing of the events differ for the different
definitions, but rather are to be examined for changes
over time. The patient group for the first two definitions
are individuals who had a baseline audiogram, whereas
the patient group for the last definition are all individ-
uals on arms C and D. At 60 days from study enroll-
ment, 6% (95% CI: 2–10) had a loss in at least one pure
tone, 7% (95% CI: 2–11) had a clinically significant loss,
and 5% (95% CI: 2–8) had a clinically significant
hearing loss and/or a hearing related adverse event of
grade 3 or higher. At 6 months, these numbers increased
to 18% (95% CI: 10–25), 19% (95% CI: 10–26), and
13% (8–18), respectively. Five patients were taken
off-study due to ototoxicity.
Univariable Cox proportional hazards models iden-
tified age as being significantly associated with a clini-
cally significant treatment-related hearing loss (hazards
ratio: 1.06, 95% CI: 1.01–1.11, P-value = 0.015). No
other baseline variable, including the baseline audio-
gram frequency values, were found to be associated with
a clinically significant hearing loss as determined by
audiogram. Age was not found to be significantly
associated with the event of a clinically significant
hearing loss and/or hearing related adverse event of
grade 3 or higher (HR = 1.03, 95% CI: 0.99–1.07,
P-value = 0.11).
Discussion
This study found a high degree of baseline hearing loss,
with 56% of patients showing at least some degree of
decreased hearing. Although the majority of these
hearing losses were at high frequencies, as would be
expected, this prevalence of decreased hearing is greater
than would be expected for patients in this age range.
This raises the question of additional mechanisms of
hearing loss in this patient population.
Conductive hearing loss was much less prevalent than
sensorineural hearing loss. Our very limited data would
seem to support that cranial radiation in GBM patients
does not pose a greatly increased risk of conductive
hearing toxicity. However, institutions had a much
poorer compliance with reporting conductive hearing
loss, which could mask significant toxicity. There were
no statistically or clinically significant differences in
hearing loss or ototoxicity between patients on arms C
and D, which suggests that accelerated radiation ther-
apy does not increase ear damage.
Controversy remains as to the proper method to
monitor cisplatin ototoxicity. Baseline screening using
audiometry has frequently been recommended [18,19].
Other studies have recommended screening only
patients with pre-determined risk factors, although these
factors vary widely. It is as yet undetermined whether
pre-treatment hearing loss does [20,21] or does not [22]
contribute to additional loss. Our study found no evi-
dence that underlying hearing loss contributed to addi-
tional loss. The only risk factor in our study shown to be
statistically significant in predicting treatment damage
was patient age above 58. Our data showing 56% of
patients having underlying hearing loss supports the
importance of baseline screening to prevent incorrect
attribution of post-treatment damage. However, the
relative infrequency of clinically significant hearing loss
in this patient population, despite concurrent RT with
CDDP, leads us to conclude that screening is most likely
unnecessary and the majority of patients do not need
audiograms unless they are symptomatic. Patients with
clinically apparent hearing loss should receive CDDP
only if there is not an appropriate alternative agent.
Conclusion
Although a large percentage of patients may show
audiogram evidence of hearing loss following this
treatment regimen, the percentage of patients with
clinically significant ototoxicity was minimal, suggesting
that screening is likely not necessary in this patient
population. This study found no evidence that acceler-
ated radiation therapy had a greater risk of ototoxicity
in combination with CDDP compared to SRT, although
the number of patients with follow-up audiograms pre-
cludes definitive comparisons. Increasing age is a risk
factor for treatment-related hearing loss.
Acknowledgements
This study was conducted as a collaborative trial of the
North Central Cancer Treatment Group and Mayo
Clinic and was supported in part by Public Health
Service Grant CA-25224, CA-37404, CA-15083, CA-
63826, CA-35103, and the National Fellowship Aca-
demic Medicine Fellowship. The authors would like to
thank Drs. Christopher Bacch and Charles Beatty for
their advice (Department of Otorhinolaryngology.
Magoclinic, Rochester, MN).
References
1. Moroso MJ, Blair RL: A review of cis-platinum ototoxicity.
J Otolaryngol 12(6): 365–369, 1983
2. Boheim K, Bichler E: Cisplatin-induced ototoxicity: audiometric
findings and experimental cochlear pathology. Arch Otorhinolar-
yngol 242(1): 1–6, 1985
3. Schaefer SD, Post JD, Close LG, Wright CG: Ototoxicity of low-
and moderate-dose cisplatin. Cancer 56(8): 1934–1939, 1985
4. Hinojosa R, Riggs LC, Strauss M, Matz GJ: Temporal bone
histopathology of cisplatin ototoxicity. Am J Otolaryng 16(6):
731–740, 1995
5. Hoistad DL, Ondrey FG, Mutlu C, Schachern PA, Paparella MM,
Adams GL: Histopathology of human temporal bone after cis-
platinum, radiation, or both. Otolaryngol Head Neck Surg 118(6):
825–832, 1998
6. Kwong DL, Wei WI, Sham JS, Ho WK, Yuen PW, Chua DT,
Au DK, Wu PM, Choy DT: Sensorineural hearing loss in patients
treated for nasopharyngeal carcinoma. A prospective study of the
effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol
Phys 36: 281–289, 1996
7. Anteunis LJ, Wanders SL, Hendriks JT, Langendijk JA, Manni JJ,
de Jong JM: A Prospective Longitudinal Study on Radiation-
Induced Hearing Loss. Am J Surg 168: 408–411, 1994
8. Kretschmar CS, Warren MP, Lavally BL, Dyer S, Tarbell NJ:
Ototoxicity of preradiation cisplatin for children with central
nervous system tumors. J Clin Oncol 8: 1191–1198, 1990
9. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Hor-
owitz M, Meyer WH: Hearing loss in children and young adults
receiving cisplatin with or without prior cranial irradiation. J Clin
Oncol 7: 754–760, 1989
10. Stewart JD, O’Bryan RM, Al-Sarraf M, Costanzi JJ, Oishi N:
Phase II study of cisplatin in recurrent astrocytomas in adults: a
Southwest Oncology Group Study. J Neurooncol 1: 145–147,
1983
11. Stewart DJ, Mikhael NZ, Nair RC, Kacew S, Montpetit V,
Nanji A, Maroun JA, Howard K: Platinum concentrations on
human autopsy tumor samples. Am J Clin Oncol 11: 152–158,
1988
12. Douple EB: Keynote address: platinum-radiation Interactions.
NCI Monograph 6: 315–319, 1988
13. Miettinen S, Laurikainen E, Johansson R, Minn H, Laurell G,
Salmi TT: Radiotherapy enhanced ototoxicity of cisplatin in
children. Acta Otolaryngol (Stockh) 529(Suppl): 90–94, 1997
14. Buckner JC, Michalak JC, Schomberg PJ, Burton GV, Sandler
HM, Cascino TL, Hawkins RB, Scheithauer BW, O’Fallon JR:
Phase III trial of BCNU plus cisplatin (CDDP) versus BCNU
alone, and standard radiation therapy (SRT) versus accelerated
radiation therapy (ART) in glioblastoma (GMB) patients (Pts):
NCCTG/SWOG results. [Abstract 219]. Proc Amer Soc Clin
Oncol 20: 56a, 2001
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete
observations. J Am Stat Assoc 3: 457–481, 1958
16. Peto R, Peto J: Asymptotically efficient rank invariant proce-
dures (with discussion). J Roy Stat Soc (Series A) 135: 185–207,
1972
17. Andersen PK, Gill RD: Cox’s regression model for counting
processes: a large sample study. Ann Stat 10: 1100–1120, 1982
18. Nagy JL, Adelsten DJ, Newman CW, Rybicki LA, Rice TW,
Lavertu P: Cisplatin ototoxicity: the importance of baseline
audiometry. Am J Clin Oncol 22(3): 305–308, 1999
19. Kujansuu E, Rahko T, Punnonen R, Karma P: Evaluation of the
hearing loss associated with cis-platinum treatment by high-
frequency audiometry. Gynecol Oncol 33(3): 321–322, 1989
20. Blakley BW, Gupta AK, Myers SF, Schwan S: Risk factors for
ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg
120: 541–546, 1994
21. Brown RL, Nuss RC, Patterson R, Irey J: Audiometric monitoring
of cis-platinum ototoxicity. Gynecol Oncol 16: 254–262, 1983
22. Durrant JD, Rodgers G, Myers EN, Johnson JT: Hearing loss –
risk factor for cisplatin ototoxicity? Observations. Am J Otol 11:
375–377, 1990
Address for offprints: Jan C. Buckner, Mayo Clinic, 200 First Street
SW, Rochester, MN, 55905, USA; Tel.: +1-507-284-4320; Fax:
+1-507-284-1803; E-mail: buckner.jan@mayo.edu
